Crossmark

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial

Published Online: 2021-10-29

Published Print: 2021-12

Authors

Hinsenveld, F. J. http://orcid.org/0000-0002-8023-6640
Noordman, B. J.

Boormans, J. L.

Voortman, J.

van Leenders, G. J. L. H.

van der Pas, S. L.

van Beek, S. C.

Oprea-Lager, D. E.

Vis, A. N.
Funding

Funding for this research was provided by:

KWF Kankerbestrijding (12432)
License Information

Text and Data Mining valid from 2021-10-29

Version of Record valid from 2021-10-29
More Information

Article History

Received: 8 June 2021

Accepted: 5 October 2021

First Online: 29 October 2021

Declarations

:

: The study has been approved by the Medical Ethical Committee of the Amsterdam University Medical Center (MEC 2019.594) on 30th January 2020. The most recent study protocol version is 6.0, date 1st February 2021. Written, voluntary, informed consent to participate in the study will be obtained from all participants. Individual patient data will not be published.

: Not applicable.

: BJN is Associate Editor of BMC Cancer. All other authors declare that they have no competing interests.

Document is current